Exploration and management of adrenal incidentalomas., Annales d'Endocrinologie, vol.69, issue.6, pp.487-500, 2008. ,
DOI : 10.1016/j.ando.2008.09.003
A disease of modern technology ,
The prevalence of adrenal incidentaloma in routine clinical practice, Endocrine, vol.54, issue.6, pp.80-83, 2011. ,
DOI : 10.1007/s12020-011-9445-6
The Incidentally Discovered Adrenal Mass, New England Journal of Medicine, vol.356, issue.6, pp.601-611, 2007. ,
DOI : 10.1056/NEJMcp065470
Prevalence and natural history of adrenal incidentalomas, European Journal of Endocrinology, vol.149, issue.4, pp.273-285, 2003. ,
DOI : 10.1530/eje.0.1490273
The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management, Endocrine Reviews, vol.25, issue.2, pp.309-349, 2004. ,
DOI : 10.1210/er.2002-0031
A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology, J Clin Endocrinol Metab, vol.85, issue.2, pp.637-681, 2000. ,
Adrenal incidentaloma - experience of a standardized diagnostic programme in the Swedish prospective study, Journal of Internal Medicine, vol.29, issue.3, pp.239-285, 2002. ,
DOI : 10.1001/jama.248.6.701
Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features, J Clin Endocrinol Metab, vol.85, issue.4, pp.1440-1448, 2000. ,
A survey on incidental adrenal tumors in Japan, Journal of Urology, vol.147, pp.1478-1481, 1992. ,
Incidentally discovered adrenal tumors: an institutional perspective, Surgery, vol.110, pp.1014-1021, 1991. ,
Development of overt Cushing's syndrome in patients with adrenal incidentaloma, European Journal of Endocrinology, vol.146, issue.1, pp.61-66, 2002. ,
DOI : 10.1530/eje.0.1460061
Evaluation of hormonal function in a series of incidentally discovered adrenal masses, Metabolism, vol.46, pp.107-113, 1997. ,
Adrenaloma: a call for a more aggressive management, World Journal of Surgery, vol.20, pp.788-793, 1996. ,
Management of incidentally discovered adrenal masses, World Journal of Urology, vol.17, issue.1, pp.9-14, 1999. ,
DOI : 10.1007/s003450050098
Incidentally discovered adrenal masses, Endocrine reviews, vol.16, pp.460-479, 1995. ,
In vivo MR spectroscopic imaging of the adrenal glands: distinction between adenomas and carcinomas larger than 15 mm based on lipid content, American Journal of Roentgenology, vol.153, issue.4, pp.771-774, 1989. ,
DOI : 10.2214/ajr.153.4.771
Distinguishing Benign from Malignant Adrenal Masses: Multi???Detector Row CT Protocol with 10-Minute Delay, Radiology, vol.238, issue.2, pp.578-85, 2006. ,
DOI : 10.1148/radiol.2382041514
Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis., Radiology, vol.179, issue.2, pp.415-423, 1991. ,
DOI : 10.1148/radiology.179.2.2014283
CT and MR Distinction of Adenomas and Nonadenomas of the Adrenal Gland, Journal of Computer Assisted Tomography, vol.18, issue.3, pp.432-440, 1994. ,
DOI : 10.1097/00004728-199405000-00017
Adrenal nonhyperfunctioning adenoma and nonadenoma: CT attenuation value as discriminative index, Abdominal Imaging, vol.15, issue.6, pp.559-62, 1995. ,
DOI : 10.1007/BF01256711
Adrenal masses: correlation between CT attenuation value and chemical shift ratio at MR imaging with in-phase and opposed-phase sequences., Radiology, vol.200, issue.3, pp.749-52, 1996. ,
DOI : 10.1148/radiology.200.3.8756926
Quantitative CT evaluation of adrenal gland masses: a step forward in the differentiation between adenomas and nonadenomas?, Radiology, vol.202, issue.2, pp.517-538, 1997. ,
DOI : 10.1148/radiology.202.2.9015083
Adrenal masses: characterization with delayed contrast-enhanced CT., Radiology, vol.202, issue.3, pp.693-699, 1997. ,
DOI : 10.1148/radiology.202.3.9051018
Clinical Utility of Noncontrast Computed Tomography Attenuation Value (Hounsfield Units) to Differentiate Adrenal Adenomas/Hyperplasias from Nonadenomas: Cleveland Clinic Experience, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.2, pp.871-878, 2005. ,
DOI : 10.1210/jc.2004-1627
Characterization of Adrenal Masses Using Unenhanced CT, The Journal of Urology, vol.171, issue.1, pp.201-205, 1998. ,
DOI : 10.1097/00005392-199901000-00122
Adrenal Masses: Characterization with Combined Unenhanced and Delayed Enhanced CT, Radiology, vol.222, issue.3, pp.629-633, 2002. ,
DOI : 10.1148/radiol.2223010766
Lipid Degeneration in Pheochromocytomas Mimicking Adrenal Cortical Tumors, The American Journal of Surgical Pathology, vol.11, issue.6, pp.480-486, 1987. ,
DOI : 10.1097/00000478-198706000-00009
A Mimicker of Adrenal Adenoma, American Journal of Roentgenology, vol.181, issue.6, pp.1663-1671, 2003. ,
DOI : 10.2214/ajr.181.6.1811663
First-pass perfusion computed tomography: Initial experience in differentiating adrenal adenoma from metastasis, European Journal of Radiology, vol.73, issue.3, pp.657-663, 2010. ,
DOI : 10.1016/j.ejrad.2009.01.007
Chemical Shift MR Imaging of Hyperattenuating (>10 HU) Adrenal Masses: Does It Still Have a Role?, Radiology, vol.231, issue.3, pp.711-717, 2004. ,
DOI : 10.1148/radiol.2313030676
MR imaging of adrenal masses: value of chemical-shift imaging for distinguishing adenomas from other tumors., American Journal of Roentgenology, vol.164, issue.3 ,
DOI : 10.2214/ajr.164.3.7863885
Distinction between benign and malignant adrenal masses: value of T1-weighted chemical-shift MR imaging., American Journal of Roentgenology, vol.165, issue.3, pp.579-83, 1995. ,
DOI : 10.2214/ajr.165.3.7645474
Differentiation of adrenal masses with MR imaging: comparison of techniques., Radiology, vol.192, issue.1, pp.41-47, 1994. ,
DOI : 10.1148/radiology.192.1.8208962
Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging., Radiology, vol.197, issue.2, pp.411-419, 1995. ,
DOI : 10.1148/radiology.197.2.7480685
Comparison of Unenhanced CT and Chemical Shift MRI in Evaluating Lipid-Rich Adrenal Adenomas, American Journal of Roentgenology, vol.183, issue.1 ,
DOI : 10.2214/ajr.183.1.1830215
Adrenal Masses: Characterization with in Vivo Proton MR Spectroscopy???Initial Experience, Radiology, vol.245, issue.3, pp.788-797, 2007. ,
DOI : 10.1148/radiol.2453061854
Distinguishing Benign from Malignant Euadrenal Masses, Mis à jour le 21 septembre 2011, pp.613-621, 1988. ,
DOI : 10.7326/0003-4819-109-8-613
Scintigraphic evaluation of clinically silent adrenal masses, J Nucl Med, vol.35, issue.7, pp.1145-52, 1994. ,
Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas, Journal of Clinical Endocrinology & Metabolism, vol.84, issue.2, pp.520-526, 1999. ,
DOI : 10.1210/jc.84.2.520
Characterization of Adrenal Masses by Using FDG PET: A Systematic Review and Meta-Analysis of Diagnostic Test Performance, Radiology, vol.259, issue.1, pp.117-126, 2011. ,
DOI : 10.1148/radiol.11100569
18F-FDG PET for the Identification of Adrenocortical Carcinomas among Indeterminate Adrenal Tumors at Computed Tomography Scanning, World Journal of Surgery, vol.238, issue.7, pp.1506-1510, 2010. ,
DOI : 10.1007/s00268-010-0576-3
Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy, European Journal of Endocrinology, vol.164, issue.1, pp.89-941605, 2006. ,
DOI : 10.1530/EJE-10-0666
Evaluation and treatment of Cushing???s syndrome, The American Journal of Medicine, vol.118, issue.12, pp.1340-1346, 2005. ,
DOI : 10.1016/j.amjmed.2005.01.059
Congenital adrenal hyperplasia presenting as massive adrenal incidentalomas in the sixth decade of life: report of two patients with 21-hydroxylase deficiency, J Clin Endocrinol Metab, vol.81, issue.5, pp.1776-1785, 1996. ,
Augmented 17??-hydroxyprogesterone response to ACTH stimulation as evidence of decreased 21-hydroxylase activity in patients with incidentally discovered adrenal tumours ('incidentalomas'), Clinical Endocrinology, vol.91, issue.4, pp.445-51, 1994. ,
DOI : 10.1210/jc.75.3.826
Clinical and Biological Features in the Prognosis of Adrenocortical Cancer: Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive Patients, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.7, pp.2650-2655, 2006. ,
DOI : 10.1210/jc.2005-2730
Diagnosis and Treatment of Subclinical Hypercortisolism, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.5, pp.1223-1236, 2011. ,
DOI : 10.1210/jc.2010-2722
Subclinical Cushing's Syndrome in Adrenal Incidentalomas, Endocrinology and Metabolism Clinics of North America, vol.34, issue.2, pp.423-462, 2005. ,
DOI : 10.1016/j.ecl.2005.01.008
Subclinical Cushing's syndrome in adrenal incidentaloma, Clinical Endocrinology, vol.121, issue.1, pp.89-97, 1998. ,
DOI : 10.1210/jc.81.2.740
AME Position Statement on adrenal incidentaloma, European Journal of Endocrinology, vol.164, issue.6, pp.851-870, 2011. ,
DOI : 10.1530/EJE-10-1147
Pros and cons of dexamethasone suppression test for screening of subclinical Cushing???s syndrome in patients with adrenal incidentalomas, Journal of Endocrinological Investigation, vol.30, issue.1, pp.1-5, 2011. ,
DOI : 10.1007/BF03346701
humoral and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery, Eur J Endocrinol. Feb, vol.148, issue.2, pp.213-222, 2003. ,
Patients with Subclinical Cushing???s Syndrome due to Adrenal Adenoma Have Increased Cardiovascular Risk, The Journal of Clinical Endocrinology & Metabolism, vol.87, issue.11, pp.4872-4880, 2002. ,
DOI : 10.1210/jc.2001-011766
Cardiovascular Risks and Their Long-Term Clinical Outcome in Patients with Subclinical Cushing's Syndrome, Endocrine Journal, vol.55, issue.4 ,
DOI : 10.1507/endocrj.K07E-177
Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study, European Journal of Endocrinology, vol.166, issue.4, pp.669-677, 2012. ,
DOI : 10.1530/EJE-11-1039
Adrenal Incidentaloma: A New Cause of the Metabolic Syndrome?, The Journal of Clinical Endocrinology & Metabolism, vol.87, issue.3, pp.998-1003, 2002. ,
DOI : 10.1210/jcem.87.3.8277
Visceral Fat Accumulation and Postdexamethasone Serum Cortisol Levels in Patients With Adrenal Incidentaloma, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.6, pp.2383-2391, 2013. ,
DOI : 10.1210/jc.2012-4276
Beneficial Metabolic Effects of Prompt Surgical Treatment in Patients with an Adrenal Incidentaloma Causing Biochemical Hypercortisolism, The Journal of Clinical Endocrinology & Metabolism, vol.95, issue.6, pp.2736-2745, 2010. ,
DOI : 10.1210/jc.2009-2387
Surgical Versus Conservative Management for Subclinical Cushing Syndrome in Adrenal Incidentalomas: A Prospective Randomized Study, Annals of Surgery, vol.249, issue.3, pp.388-391, 2009. ,
DOI : 10.1097/SLA.0b013e31819a47d2
Evaluation of the Cardiovascular Risk in Patients with Subclinical Cushing Syndrome Before and After Surgery, World Journal of Surgery, vol.7, issue.9, pp.1665-1671, 2006. ,
DOI : 10.1007/s00268-005-0681-x
Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study Subclinical Cushing's syndrome, PLoS One. Pituitary, vol.8, issue.74, pp.217-240, 2004. ,
Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome, J Clin Endocrinol Metab, vol.86, issue.11, pp.5301-5307, 2001. ,
Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours, Clinical Endocrinology, vol.60, issue.1, pp.53-61, 1998. ,
DOI : 10.1016/S0140-6736(85)92964-2
Nondiabetic patients with either subclinical Cushing's or nonfunctional adrenal incidentalomas have lower insulin sensitivity than healthy controls: Clinical implications, Metabolism, vol.62, issue.6, pp.786-92, 2013. ,
DOI : 10.1016/j.metabol.2012.12.006
Adequately Adapted Insulin Secretion and Decreased Hepatic Insulin Extraction Cause Elevated Insulin Concentrations in Insulin Resistant Non-Diabetic Adrenal Incidentaloma Patients, PLoS ONE, vol.18, issue.10, p.77326, 2013. ,
DOI : 10.1371/journal.pone.0077326.t002
The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection, Clinical Endocrinology, vol.43, issue.6 ,
DOI : 10.1210/jc.81.2.740
Syndrome de Cushing infra-clinique : impact de la surrénalectomie sur les paramètres métaboliques pré-opératoires, 2010. ,
Adrenal cortical carcinoma, World Journal of Surgery, vol.12, issue.7, pp.914-940, 2001. ,
DOI : 10.1007/s00268-001-0030-7
RE, The Journal of Urology, vol.161, issue.5, pp.1580-1581, 1999. ,
DOI : 10.1097/00005392-199905000-00053
Management of patients with adrenal cancer: recommendations of an international consensus conference, Endocrine Related Cancer, vol.12, issue.3 ,
DOI : 10.1677/erc.1.01029
Laparoscopic versus open posterior adrenalectomy: A case-control study of 100 patients, Surgery, vol.122, issue.6, pp.1132-1138, 1997. ,
DOI : 10.1016/S0039-6060(97)90218-X
LAPAROSCOPIC ADRENALECTOMY, The Journal of Urology, vol.160, issue.2, pp.325-334, 1998. ,
DOI : 10.1097/00005392-199808000-00006
Eightyear experience with transperitoneal laparoscopic adrenal surgery, J Urol, 2001. ,
Morbidity of unilateral and bilateral laparoscopic adrenalectomy according to the indication Report of a series of 100 consecutive cases, Prog Urol, vol.15, issue.4, pp.626-657, 2005. ,
Long-term Outcome following Laparoscopic Adrenalectomy for Large Solid Adrenal Cortex Tumors, World Journal of Surgery, vol.157, issue.5, pp.893-901, 2006. ,
DOI : 10.1007/s00268-005-0288-2
COMPARISON OF 3 SURGICAL APPROACHES TO LAPAROSCOPIC ADRENALECTOMY, The Journal of Urology, vol.166, issue.2, pp.437-480, 2001. ,
DOI : 10.1097/00005392-200108000-00009
Laparoscopic partial adrenalectomy in patients with aldosterone-producing adenomas: indications, technique, and results, Urology, vol.61, issue.1, pp.69-72, 2003. ,
DOI : 10.1016/S0090-4295(02)02240-9
Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas, British Journal of Cancer, vol.202, issue.6, pp.1104-1109, 2005. ,
DOI : 10.1097/00001622-200301000-00013
Incidentaloma, Adrenal, pp.757-761, 1996. ,
DOI : 10.1016/B0-12-475570-4/00747-2
Glucocorticoids and insulin resistance: old hormones, new targets, Clinical Science, vol.96, issue.5, pp.513-523, 1999. ,
DOI : 10.1042/cs0960513
Central regulation of parasympathic drive to pancreatic ?cells in the obese fa/fa rat, Int. J. Obes, vol.15, pp.547-553, 1991. ,
Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids., Journal of Clinical Investigation, vol.100, issue.8, pp.2094-2102, 1997. ,
DOI : 10.1172/JCI119743
Le dialogue intra-surrénalien dans les hypercorticismes: perspectives thérapeutiques. Conférence présentée aux trente-troisièmes journées Nicolas Guéritée d'endocrinologie et maladies métaboliques, 2013. ,
Intraadrenal Adrenocorticotropin Production in a Case of Bilateral Macronodular Adrenal Hyperplasia Causing Cushing???s Syndrome, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.7, pp.3035-3042, 2003. ,
DOI : 10.1210/jc.2002-030014
Screening for Illegitimate Receptors in Adrenocorticotropin-Independent Macronodular Adrenal Hyperplasia Causing Cushing???s Syndrome: Identification of Two Cases of Gonadotropin/Gastric Inhibitory Polypeptide-Dependent Hypercortisolism, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.3, pp.1302-1310, 2005. ,
DOI : 10.1210/jc.2004-1256
Aberrant adrenal sensitivity to vasopressin in adrenal tumours associated with subclinical or overt autonomous hypercortisolism: is this explained by an overexpression of vasopressin receptors?, Clinical Endocrinology, vol.48, issue.5, pp.692-699, 2008. ,
DOI : 10.1210/jc.2002-030014
Intraadrenal Interactions in the Regulation of Adrenocortical Steroidogenesis, Endocrine Reviews, vol.19, issue.2, pp.101-143, 1998. ,
DOI : 10.1210/edrv.19.2.0326
Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action, European Journal of Endocrinology, vol.149, issue.3, pp.163-168, 2003. ,
DOI : 10.1530/eje.0.1490163
11??-Hydroxysteroid dehydrogenase type 1 shRNA ameliorates glucocorticoid-induced insulin resistance and lipolysis in mouse abdominal adipose tissue, AJP: Endocrinology and Metabolism, vol.308, issue.1, pp.84-95, 2015. ,
DOI : 10.1152/ajpendo.00205.2014
Role of Local 11??-Hydroxysteroid Dehydrogenase Type 2 Expression in Determining the Phenotype of Adrenal Adenomas, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.2, pp.864-870, 2003. ,
DOI : 10.1210/jc.2001-011335
microRNA-379 couples glucocorticoid hormones to dysfunctional lipid homeostasis, The EMBO Journal, vol.34, issue.3, pp.344-60, 2015. ,
DOI : 10.15252/embj.201490464
A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome, Proceedings of the National Academy of Sciences, vol.112, issue.1, pp.285-90, 2015. ,
DOI : 10.1073/pnas.1421420112
Obesity, haemostasis and the fibrinolytic system, Obesity Reviews, vol.19, issue.2, pp.85-101, 2002. ,
DOI : 10.1038/sj.ijo.0801087
Hypofibrinolysis and the insulin resistance syndrome, Int J Obes Relat Metab Disord, vol.19, issue.1, pp.11-16, 1995. ,
Effect of Angiotensin Peptides on PAI-1 Expression and Production in Human Adipocytes, Hormone and Metabolic Research, vol.33, issue.4, pp.196-200, 2001. ,
DOI : 10.1055/s-2001-14948
Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholaminess, J Clin Endocrinol Metab, vol.84, issue.11, pp.4097-105, 1999. ,
Blood coagulation and fibrinolysis in patients with Cushing???s syndrome: Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels, Journal of Endocrinological Investigation, vol.22, issue.2, pp.169-74, 2009. ,
DOI : 10.1007/BF03345709
Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery, European Journal of Endocrinology, vol.163, issue.5, pp.783-791, 2010. ,
DOI : 10.1530/EJE-10-0583
Hypercoagulability in Cushing???s syndrome: the role of specific haemostatic and fibrinolytic markers, Endocrine, vol.87, issue.1, pp.70-74, 2009. ,
DOI : 10.1007/s12020-009-9186-y
The Hypercoagulable State in Cushing's Disease Is Associated with Increased Levels of Procoagulant Factors and Impaired Fibrinolysis, But Is Not Reversible after Short-Term Biochemical Remission Induced by Medical Therapy, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.4, pp.1303-1310, 2012. ,
DOI : 10.1210/jc.2011-2753
The fibrinolytic potential in patients with Cushing??s disease, Blood Coagulation & Fibrinolysis, vol.3, issue.6, pp.789-793, 1992. ,
DOI : 10.1097/00001721-199212000-00013
Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris ,
Biochemical Basis for the Hypercoagulable State Seen in Cushing Syndrome, Archives of Surgery, vol.136, issue.9, pp.1003-1006, 2001. ,
DOI : 10.1001/archsurg.136.9.1003
Mortality in Cushing's syndrome: A systematic review and meta-analysis, European Journal of Internal Medicine, vol.23, issue.3, pp.278-282, 2012. ,
DOI : 10.1016/j.ejim.2011.10.013
Multisystem Morbidity and Mortality in Cushing's Syndrome: A Cohort Study, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.6, pp.2277-2284, 2013. ,
DOI : 10.1210/jc.2012-3582
Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment, Clinical Endocrinology, vol.20, issue.10-12, pp.481-488, 2013. ,
DOI : 10.1111/cen.12094
The spectrum of haemostatic abnormalities in glucocorticoid excess and defect, Eur J Endocrinol. first published on, 2015. ,
The estimation of selected endogenous anticoagulation system parameters in patients with subclinical Cushing's syndrome, European Journal of Endocrinology, vol.165, issue.6, pp.865-871, 2011. ,
DOI : 10.1530/EJE-11-0535
Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma, Experimental and Clinical Endocrinology & Diabetes, vol.108, issue.4, pp.294-302, 2000. ,
DOI : 10.1055/s-2000-8000
Prospective study of endogenous tissue plasminogen activator and risk of stroke, The Lancet, vol.343, issue.8903, pp.940-943, 1994. ,
DOI : 10.1016/S0140-6736(94)90064-7
Fibrinogen as a Cardiovascular Risk Factor, Annals of Internal Medicine, vol.118, issue.12, pp.956-963, 1993. ,
DOI : 10.7326/0003-4819-118-12-199306150-00008
Cortisol as a Marker for Increased Mortality in Patients with Incidental Adrenocortical Adenomas, The Journal of Clinical Endocrinology & Metabolism, vol.99, issue.12, p.20143007, 2014. ,
DOI : 10.1210/jc.2014-3007
Subclinical Cushing's syndrome. Endocrinology and metabolism Clinics of, North America, vol.29, pp.43-56, 2000. ,
Bone Mineral Density, Prevalence of Vertebral Fractures, and Bone Quality in Patients with Adrenal Incidentalomas with and without Subclinical Hypercortisolism: An Italian Multicenter Study, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.9, pp.3207-3214, 2009. ,
DOI : 10.1210/jc.2009-0468
Epidémiologie du syndrome métabolique et du risque cardiovasculaire ,
Role of glucocorticoid receptor polymorphism in adrenal incidentalomas, European Journal of Clinical Investigation, vol.32, issue.9, pp.803-814, 2010. ,
DOI : 10.1111/j.1365-2362.2010.02330.x
Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance, JAMA, vol.290, issue.4, pp.486-494, 2003. ,
DOI : 10.1001/jama.290.4.486
Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas, Clinical Endocrinology, vol.121, issue.2, pp.165-171, 1998. ,
DOI : 10.1046/j.1365-2265.1997.1580969.x
Pathophysiological Mechanisms of Tobacco-Related CVD. Glob Heart, pp.113-133, 2012. ,